Research Project
9202154
Despite the recent development of novel therapeutic approaches, no curative treatment is available for advanced stage melanoma, with 5-year survival below 15%. Targeted therapy is one of the most promising therapeutic strategies to the treatment of cancer and is a key component of precision medicine, which aims to individualize cancer treatment for a given patient. IL-13RA2, an oncogenic isoform of the ubiquitous IL-13RA1 receptor, is overexpressed in primary and metastatic melanomas, but not in normal tissue. This receptor has been underutilized therapeutically, partly due to the lack of clinically applicable translational tools. Recently, a novel class of unique ligands has been developed that not only selectively bind the IL-13RA2 receptor but also, after internalization, reach the desired cellular compartment including the nucleus. Specifically, we hypothesize that our patented DNA binding agent showing nanomolar potency (IC50~4 nM or lower) against melanoma cells but not normal cells (no effect at 1,000 nM), when conjugated to IL- 13RA2-specific ligands capable of delivering a payload to the nucleus or cytoplasm of melanoma tumor cells, will generate a new class of highly efficacious melanoma selective therapeutic agents with great translational and commercial potential. We propose two specific aims. Aim 1: To develop ligand-drug conjugates targeting melanoma tumors expressing the IL-13RA2 receptor. Two conjugation strategies will be employed: delivering either a stable drug conjugate containing domains critical for nuclear delivery of the payload or a pH sensitive linker that liberates drug from the internalized conjugates in the lumen of endocytic vesicles to the cytosol and other organs. Aim 2: To assess in vitro and in vivo efficacy of the conjugates in melanoma models with variable expression of IL13-RA2. We will test and compare the efficacy of synthesized conjugates in vitro and in vivo models using cells/tumors with both high and low expression of the IL-13RA2 receptor. In summary, we propose to develop a new, unique, and highly promising targeted therapy, both conceptually and practically, for melanoma patients. This concept has a double advantage as it combines (1) selectively binding melanoma cells ligands with (2) a melanoma-specific, highly cytotoxic DNA binding agent. This double-advantage approach will explore ligands that not only bind to the IL-13RA2 receptor on melanoma, but are internalized to deliver a cytotoxic payload to the desired cellular compartment. This further increases the chances of developing safe and efficacious targeted therapeutics with increased potency and selectivity. The results of these innovative studies will deliver the required proof of principle and will support the Phase 2 SBIR grant application for advanced preclinical development aimed at the initiation of clinical studies in humans and the subsequent commercialization of validated conjugate.
